EB
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study | Clinical infectious diseases |  | 2025 | 9 | 37 | ||
| Low Trauma Fractures in People with HIV : Longitudinal Time Trends in the Swiss HIV Cohort Study 2009-2022 | Clinical infectious diseases | | 2025 | 13 | 25 | ||
| Polygenic Risk Scores for Type 2 Diabetes in the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes |  | 2025 | 17 | 0 | ||
| Machine Learning-based Prediction of Active Tuberculosis in People With HIV Using Clinical Data | Clinical infectious diseases | | 2025 | 7 | 20 | ||
| Untargeted Metabolite Profile Associations with Body Mass Index, Waist-Hip Ratio, and Antiretroviral Therapy in >1300 People with HIV : the Swiss HIV Cohort Study | The journal of infectious diseases | | 2025 | 6 | 20 | ||
| Types of Myocardial Infarction in People With HIV in Switzerland | Open forum infectious diseases | | 2025 | 8 | 27 | ||
| Infection with Mycobacterium tuberculosis alters the antibody response to HIV-1 | PLOS pathogens | | 2025 | 6 | 35 | ||
| Late Re-Engagement Into HIV Care Among Adults in the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | | 2025 | 15 | 0 | ||
| Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program : A Data Linkage Study of Claims and Swiss HIV Cohort Study Data | Open forum infectious diseases | | 2025 | 8 | 8 | ||
| Frequent hepatitis B surface antigen (HBsAg) clearance during tenofovir therapy in persons with HIV/hepatitis B virus coinfection | HIV medicine | | 2025 | 12 | 0 | ||
| Leukocyte count and new-onset diabetes mellitus in people with HIV : A longitudinal study | HIV medicine | | 2025 | 11 | 13 | ||
| Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment-experienced people living with HIV : A feasibility survey | HIV medicine | | 2025 | 9 | 24 | ||
| Implementing a randomization consent to enable Trials within Cohorts in the Swiss HIV Cohort Study - A mixed-methods study | Journal of clinical epidemiology | | 2025 | 10 | 33 | ||
| Test and treat-impact of microbiological testing on antibiotic prescribing for Legionnaires' disease in Switzerland : results of the multicentre SwissLEGIO study | Pneumonia | | 2025 | 6 | 15 | ||
| Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy design | The journal of experimental medicine | | 2025 | 7 | 31 | ||
| External Validation of Serologic Scores for the Detection of Liver Steatosis Among People With HIV | Open forum infectious diseases | | 2024 | 8 | 26 | ||
| Time Trends in Causes of Death in People With HIV : Insights From the Swiss HIV Cohort Study | Clinical infectious diseases | | 2024 | 8 | 39 | ||
| Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine : a multicenter prospective observational study in Switzerland | The Lancet regional health. Europe | | 2024 | 6 | 36 | ||
| Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression : Results Through Week 144 of the SIMPL'HIV Trial | Open forum infectious diseases | | 2024 | 6 | 38 | ||
| Characterization and Determinants of Long-Term Immune Recovery Under Suppressive Antiretroviral Therapy | Journal of acquired immune deficiency syndromes | | 2024 | 9 | 8 | ||
| Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk | Open forum infectious diseases | | 2024 | 4 | 12 | ||
| Infectious disease events in people with HIV receiving kidney transplantation : Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study | BMC infectious diseases | | 2024 | 62 | 94 | ||
| Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV | Frontiers in pharmacology | | 2024 | 5 | 10 | ||
| Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV | Clinical infectious diseases | | 2024 | 4 | 22 | ||
| Cohort profile : the Swiss Mother and Child HIV Cohort Study (MoCHiV) | BMJ open | | 2024 | 5 | 8 | ||
| Patient and public involvement in HIV research : a mapping review and development of an online evidence map | Journal of the International AIDS Society | | 2024 | 3 | 26 | ||
| Self-reported neurocognitive complaints in the Swiss HIV Cohort Study : a viral genome-wide association study | Brain communications | | 2024 | 8 | 18 | ||
| Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities | HIV medicine | | 2024 | 4 | 17 | ||
| Transcriptional profile of Mycobacterium tuberculosis infection in people living with HIV | iScience | | 2024 | 7 | 9 | ||
| Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy : the SIMPL'HIV open-label, factorial randomised controlled trial | Swiss medical weekly | | 2024 | 12 | 31 | ||
| Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV) : a multicenter, international, non-randomized clinical trial study protocol | BMC infectious diseases | | 2024 | 124 | 128 | ||
| Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study | The journal of infectious diseases | | 2024 | 7 | 10 | ||
| Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy | The journal of infectious diseases | | 2024 | 4 | 12 | ||
| Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV | Clinical pharmacology and therapeutics | | 2024 | 91 | 145 | ||
| Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3) | The journal of infectious diseases | | 2024 | 517 | 469 | ||
| Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study | Liver international | | 2024 | 6 | 35 | ||
| Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies | The journal of experimental medicine | | 2024 | 5 | 17 | ||
| Booster-free anti-retroviral therapy for persons living with HIV and multidrug resistance (B-Free) : protocol for a multicentre, multistage, randomised, controlled, non-inferiority trial | BMJ open | | 2024 | 3 | 8 | ||
| Trends in Mortality in People With HIV From 1999 through 2020 : A Multicohort Collaboration | Clinical infectious diseases | | 2024 | 6 | 7 | ||
| Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy | HIV medicine | | 2024 | 15 | 28 | ||
| Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy | Clinical infectious diseases | | 2023 | 103 | 110 | ||
| Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV) : A Study Combining Modelling and Swiss HIV Cohort Data | Clinical infectious diseases | | 2023 | 116 | 86 | ||
| Viral suppression and retention in HIV care during the postpartum period among women living with HIV : a longitudinal multicenter cohort study | The Lancet regional health. Europe | | 2023 | 65 | 18 | ||
| Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor‐containing regimen | British journal of clinical pharmacology | | 2023 | 105 | 83 | ||
| External validation of the Dat'AIDS score : A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or older | HIV medicine | | 2023 | 94 | 69 | ||
| Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection | Clinical infectious diseases | | 2023 | 112 | 0 | ||
| Incidence of sexually transmitted infections and association with behavioural factors: Time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohort | HIV medicine | | 2023 | 90 | 278 | ||
| Comparison of five different risk scores to predict incident type 2 diabetes in the Swiss HIV cohort study | AIDS | | 2023 | 117 | 52 | ||
| Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV : The Swiss HIV Cohort Study | The Journal of infectious diseases | | 2023 | 96 | 47 | ||
| Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2) | Open forum infectious diseases | | 2023 | 92 | 68 | ||
| Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus (HIV) in Switzerland | Clinical infectious diseases | | 2023 | 106 | 45 | ||
| Triggers of change in sexual behavior among people with HIV: The Swiss U = U statement and Covid-19 compared | The journal of infectious diseases | | 2023 | 117 | 81 | ||
| Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons With Human Immunodeficiency Virus (HIV): The Swiss HIV Cohort Study | Clinical infectious diseases | | 2023 | 101 | 43 | ||
| Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2 : Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2) | Open forum infectious diseases | | 2023 | 140 | 85 | ||
| Sexual Behaviour and STI Incidence in Sexually Active MSM Living With HIV in Times of COVID-19 | Open forum infectious diseases | | 2023 | 127 | 137 | ||
| Legionnaires' disease in Switzerland: rationale and study protocol of a prospective national case-control and molecular source attribution study (SwissLEGIO) | Infection | | 2023 | 73 | 123 | ||
| A Phylogeny-aware GWAS Framework to Correct for Heritable Pathogen Effects on Infectious Disease Traits | Molecular biology and evolution | | 2022 | 164 | 107 | ||
| Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics | Journal of acquired immune deficiency syndromes | | 2022 | 188 | 67 | ||
| An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters | Viruses | | 2022 | 98 | 24 | ||
| LOw-dose CT Or Lung UltraSonography versus standard of care based-strategies for the diagnosis of pneumonia in the elderly: protocol for a multicentre randomised controlled trial (OCTOPLUS) | BMJ open | | 2022 | 167 | 114 | ||
| Female Genital Mutilation/Cutting in the Swiss HIV Cohort Study: A Cross-Sectional Study | Journal of immigrant and minority health | | 2022 | 91 | 94 | ||
| Transfer of antiretroviral drugs into breastmilk : a prospective study from the Swiss Mother and Child HIV Cohort Study | Journal of antimicrobial chemotherapy | | 2022 | 95 | 59 | ||
| A Systematic Molecular Epidemiology Screen Reveals Numerous Human Immunodeficiency Virus (HIV) Type 1 Superinfections in the Swiss HIV Cohort Study | The journal of infectious diseases | | 2022 | 125 | 0 | ||
| Impact of interactive computerised decision support for hospital antibiotic use (COMPASS): an open-label, cluster-randomised trial in three Swiss hospitals | Lancet. Infectious diseases | | 2022 | 232 | 514 | ||
| Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study | The journal of antimicrobial chemotherapy | | 2022 | 102 | 0 | ||
| Anticholinergic and sedative medications are associated with neurocognitive performance of well treated people with human immunodeficiency virus | Open forum infectious diseases | | 2022 | 93 | 111 | ||
| A highly virulent variant of HIV-1 circulating in the Netherlands | Science | | 2022 | 197 | 77 | ||
| Risk Factors and Incidence of Sexually Transmitted Infections in the Swiss HIV Cohort Study | Open forum infectious diseases | | 2022 | 212 | 526 | ||
| Decrease of condom use in heterosexual couples and its impact on pregnancy rates: the Swiss HIV Cohort Study (SHCS) | HIV medicine | | 2022 | 116 | 99 | ||
| Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission | HIV Medicine | | 2021 | 266 | 0 | ||
| Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study | Open Forum Infectious Diseases | | 2021 | 318 | 178 | ||
| Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link | eLife | | 2021 | 174 | 83 | ||
| The role of Human Immunodeficiency Virus (HIV) asymptomatic status when starting antiretroviral therapy on adherence and treatment outcomes and implications for test and treat: the swiss HIV Cohort Study | Clinical Infectious Diseases | | 2021 | 159 | 0 | ||
| Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis | Nature communications | | 2021 | 84 | 13 | ||
| Identifying and characterizing trans women in the swiss HIV Cohort Study as an epidemiologically distinct risk group | Clinical Infectious Diseases | | 2021 | 197 | 0 | ||
| Increasing Frequency and Transmission of HIV-1 Non-B Subtypes among Men Who Have Sex with Men in the Swiss HIV Cohort Study | The Journal of Infectious Diseases | | 2021 | 170 | 0 | ||
| Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial | EClinicalMedicine | | 2021 | 645 | 166 | ||
| Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study | Annals of internal medicine | | 2021 | 212 | 0 | ||
| Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study : 1980-2018 | Antiviral therapy | | 2020 | 72 | 0 | ||
| HCV genetic diversity can be used to infer infection recency and time since infection | Viruses | | 2020 | 229 | 101 | ||
| Host genomics of the HIV-1 reservoir size and its decay rate during suppressive antiretroviral treatment | Journal of Acquired Immune Deficiency Syndromes | | 2020 | 227 | 0 | ||
| Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV | PLoS biology | | 2020 | 97 | 28 | ||
| Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial | PLoS medicine | | 2020 | 227 | 204 | ||
| Repeated syphilis episodes in HIV-infected men who have sex with men: a multicenter prospective cohort study on risk factors and the potential role of syphilis immunity | Open Forum Infectious Diseases | | 2020 | 302 | 143 | ||
| Phylogenetic cluster analysis identifies virological and behavioral drivers of HIV transmission in MSM | Clinical Infectious Diseases | | 2020 | 388 | 12 | ||
| How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population? | HIV medicine | | 2020 | 118 | 46 | ||
| Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART | Nature Communications | | 2020 | 261 | 81 | ||
| Contribution of Genetic Background and Data Collection on Adverse Events of Anti–human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate | Clinical Infectious Diseases | | 2020 | 275 | 0 | ||
| Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients | Clinical Infectious Diseases | | 2020 | 371 | 3 | ||
| Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART | Nature Communications | | 2019 | 310 | 149 | ||
| Impact of the M184V/I Mutation on the efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV treatment-experienced patients | Open Forum Infectious Diseases | | 2019 | 303 | 249 | ||
| HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected | Journal of Acquired Immune Deficiency Syndromes | | 2019 | 326 | 0 | ||
| Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence | The journal of antimicrobial chemotherapy | | 2019 | 84 | 0 | ||
| Changing trends in international versus domestic HCV transmission in HIV-positive MSM: A perspective for the DAA scale-up era | The Journal of Infectious Diseases | | 2019 | 816 | 254 | ||
| Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction | International Journal of Cancer | | 2019 | 309 | 207 | ||
| A systematic phylogenetic approach to study the interaction of HIV-1 with coinfections, noncommunicable diseases, and opportunistic diseases | The Journal of Infectious Diseases | | 2019 | 354 | 0 | ||
| Why do sub‐Saharan Africans present late for HIV care in Switzerland ? | HIV medicine | | 2019 | 89 | 0 | ||
| Viral diversity based on next-generation sequencing of HIV-1 provides precise estimates of infection recency and time since infection | The Journal of Infectious Diseases | | 2019 | 303 | 0 | ||
| On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: A mathematical modelling study | Journal of viral hepatitis | | 2018 | 1,749 | 476 | ||
| Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study | Liver International | | 2018 | 485 | 0 | ||
| Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study | Virus Evolution | | 2018 | 388 | 105 | ||
| Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID Study | Kidney International Reports | | 2018 | 495 | 161 | ||
| The cumulative impact of harm reduction on the swiss HIV epidemic: cohort study, mathematical model, and phylogenetic analysis | Open Forum Infectious Diseases | | 2018 | 378 | 205 | ||
| Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity | Molecular Biology and Evolution | | 2018 | 505 | 220 | ||
| Is breastfeeding an equipoise option in effectively treated HIV-infected mothers in a high-income setting? | Swiss Medical Weekly | | 2018 | 477 | 0 | ||
| Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland | HIV Medicine | | 2018 | 609 | 0 | ||
| Study protocol for a multicentre, cluster randomised, superiority trial evaluating the impact of computerised decision support, audit and feedback on antibiotic use: the COMPuterized Antibiotic Stewardship Study (COMPASS) | BMJ Open | | 2018 | 586 | 279 | ||
| Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity | The Journal of experimental medicine | | 2018 | 309 | 124 | ||
| Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals | Medicine (Philadelphia) | | 2017 | 411 | 181 | ||
| Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population | AIDS | | 2017 | 413 | 292 | ||
| Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis | eLife | | 2017 | 501 | 189 | ||
| Hepatitis delta-associated mortality in HIV/HBV-coinfected patients | Journal of Hepatology | | 2017 | 430 | 534 | ||
| Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort Study | HIV Medicine | | 2017 | 388 | 0 | ||
| High prevalence of physical inactivity among patients from the Swiss HIV Cohort Study | AIDS Care | | 2017 | 412 | 618 | ||
| Human papillomavirus antibody response following HAART initiation among MSM | AIDS | | 2017 | 429 | 0 | ||
| Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study | Clinical Infectious Diseases | | 2017 | 396 | 0 | ||
| Adverse events of raltegravir and dolutegravir | AIDS | | 2017 | 427 | 177 | ||
| Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study | BMC Infectious Diseases | | 2017 | 423 | 178 | ||
| Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships | HIV Medicine | | 2017 | 448 | 0 | ||
| Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial | The Lancet Infectious Diseases | | 2017 | 562 | 0 | ||
| Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared | International journal of infectious diseases | | 2016 | 513 | 173 | ||
| Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions | Hepatology | | 2016 | 707 | 314 | ||
| Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland | Scientific Reports | | 2016 | 1,094 | 287 | ||
| Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort Study | Open Forum Infectious Diseases | | 2016 | 486 | 260 | ||
| Determinants of HIV-1 broadly neutralizing antibody induction | Nature Medicine | | 2016 | 566 | 424 | ||
| Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study | The Journal of Infectious Diseases | | 2016 | 423 | 242 | ||
| Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: A nested case-control study in the Swiss HIV cohort study | International journal of cancer | | 2016 | 693 | 315 | ||
| Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis | Clinical Infectious Diseases | | 2016 | 681 | 1 | ||
| HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study | Clinical Infectious Diseases | | 2016 | 519 | 201 | ||
| Postnatal retention in HIV care: insight from the Swiss HIV Cohort Study over a 15-year observational period | HIV medicine | | 2016 | 511 | 0 | ||
| Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland | AIDS | | 2015 | 94 | 0 | ||
| Reasons for late presentation to HIV care in Switzerland | Journal of the International AIDS Society | | 2015 | 74 | 42 | ||
| Syphilis: Diagnostik und Behandlung | Swiss Medical Forum | | 2015 | 385 | 947 | ||
| Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012 | The Journal of infectious diseases | | 2015 | 606 | 0 | ||
| Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population | Open forum infectious diseases | | 2015 | 604 | 255 | ||
| Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders | AIDS research and therapy | | 2015 | 625 | 326 | ||
| Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study | Journal of Antimicrobial Chemotherapy | | 2015 | 447 | 187 | ||
| Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV | International journal of epidemiology | | 2014 | 772 | 442 | ||
| Disentangling human tolerance and resistance against HIV | PLoS biology | | 2014 | 667 | 348 | ||
| The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients | AIDS | | 2014 | 570 | 0 | ||
| AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to be | Journal of the International AIDS Society | | 2014 | 638 | 291 | ||
| Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients | AIDS | | 2014 | 572 | 0 | ||
| Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study | Clinical infectious diseases | | 2014 | 718 | 0 | ||
| Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in Switzerland | American journal of epidemiology | | 2014 | 871 | 69 | ||
| Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide | The Journal of infectious diseases | | 2014 | 605 | 0 | ||
| Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study | Open forum infectious diseases | | 2014 | 986 | 356 | ||
| Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection | The Journal of infectious diseases | | 2013 | 657 | 0 | ||
| High proportion of healthcare-associated urinary tract infection in the absence of prior exposure to urinary catheter: a cross-sectional study | Antimicrobial resistance and infection control | | 2013 | 682 | 1,442 | ||
| Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study | HIV medicine | | 2013 | 643 | 0 | ||
| The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients | PLoS computational biology | | 2013 | 708 | 279 | ||
| HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis | PLOS genetics | | 2013 | 929 | 640 | ||
| Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals | Pharmacogenetics and genomics | | 2013 | 663 | 0 | ||
| Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study | PloS one | | 2013 | 624 | 593 | ||
| Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS) | Journal of acquired immune deficiency syndromes | | 2013 | 610 | 0 | ||
| A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control | eLife | | 2013 | 643 | 285 | ||
| Association of Alcohol Consumption and HIV Surrogate Markers in Participants of the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | | 2013 | 576 | 0 | ||
| The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study | Antiviral therapy | 2013 | 746 | 0 | |||
| Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study | The Journal of infectious diseases | | 2013 | 652 | 0 | ||
| Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection | British journal of cancer | | 2012 | 585 | 1,081 | ||
| Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir | AIDS | | 2012 | 616 | 0 | ||
| Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens | PloS one | | 2012 | 642 | 278 | ||
| Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians | HIV medicine | | 2012 | 598 | 0 | ||
| Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic | Clinical infectious diseases | | 2012 | 563 | 0 | ||
| Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations | Clinical infectious diseases | | 2012 | 1,079 | 314 | ||
| Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | | 2012 | 637 | 0 | ||
| Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study | HIV medicine | | 2012 | 637 | 1 | ||
| Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients | PloS one | | 2012 | 637 | 242 | ||
| Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes | PloS one | | 2012 | 651 | 498 | ||
| Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B | Clinical infectious diseases | | 2011 | 594 | 395 | ||
| Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection | Clinical infectious diseases | | 2011 | 907 | 784 | ||
| Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study | HIV medicine | | 2011 | 639 | 0 | ||
| Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients : The ACHIEV2E Collaboration Study Group | Clinical infectious diseases | | 2011 | 104 | 0 | ||
| Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals: the Swiss HIV Cohort Study | Journal of translational medicine | | 2011 | 665 | 303 | ||
| Overall burden of healthcare-associated infections among surgical patients. Results of a national study | Annals of surgery | | 2011 | 587 | 0 | ||
| The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland | The Journal of infectious diseases | | 2011 | 672 | 618 | ||
| Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors | Journal of acquired immune deficiency syndromes | | 2011 | 720 | 1,631 | ||
| No Longitudinal Mitochondrial DNA Sequence Changes in HIV-infected Individuals With and Without Lipoatrophy | Scandinavian journal of infectious diseases | | 2011 | 980 | 235 | ||
| A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel | Liver international | | 2011 | 646 | 0 | ||
| Clinical relevance of cytomegalovirus viraemia | HIV medicine | | 2011 | 659 | 0 | ||
| Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy | Gut | | 2010 | 660 | 0 | ||
| Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study | Antiviral therapy | 2010 | 573 | 0 | |||
| Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV Cohort Study | AIDS | | 2010 | 269 | 0 | ||
| Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | | 2010 | 583 | 0 | ||
| Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008 | The American journal of psychiatry | 2010 | 689 | 0 | |||
| Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland | The Journal of infectious diseases | | 2010 | 618 | 0 | ||
| Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load | PLOS pathogens | | 2010 | 747 | 511 | ||
| Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study | AIDS research and human retroviruses | | 2010 | 615 | 0 | ||
| Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia | Clinical infectious diseases | | 2010 | 616 | 0 | ||
| Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals | Clinical infectious diseases | | 2010 | 657 | 0 | ||
| Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study | Clinical infectious diseases | | 2010 | 615 | 0 | ||
| Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008 | Archives of internal medicine | | 2010 | 558 | 0 | ||
| Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study | Schweizerische medizinische Wochenschrift | 2010 | 706 | 0 | |||
| Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection | Clinical infectious diseases | | 2010 | 529 | 0 | ||
| Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study | Gastroenterology | | 2010 | 894 | 0 | ||
| Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study | HIV medicine | | 2009 | 630 | 0 | ||
| Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy | Journal of clinical epidemiology | | 2009 | 503 | 0 | ||
| Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study | HIV medicine | | 2009 | 497 | 0 | ||
| How reliable is an undetectable viral load? | HIV medicine | | 2009 | 569 | 0 | ||
| Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine : a nested case-control study | Clinical infectious diseases | | 2009 | 79 | 0 | ||
| Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007 | PloS one | | 2009 | 1,129 | 809 | ||
| Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study | Antiviral therapy | 2009 | 523 | 0 | |||
| Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals | HIV clinical trials | 2009 | 530 | 0 | |||
| Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland | Clinical infectious diseases | | 2009 | 642 | 0 | ||
| Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study | Circulation. Cardiovascular genetics | | 2009 | 540 | 0 | ||
| Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV | Antiviral therapy | 2009 | 590 | 0 | |||
| HIV transmission under highly active antiretroviral therapy | Lancet | | 2008 | 595 | 0 | ||
| Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir | Clinical infectious diseases | | 2008 | 589 | 0 | ||
| Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication | European Journal of Immunology | | 2008 | 679 | 0 | ||
| Dix ans de lipodystrophie (1998-2008) : un syndrome encore méconnu | Revue médicale suisse | | 2008 | 589 | 195 | ||
| Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study | HIV medicine | | 2008 | 604 | 0 | ||
| Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study | The Journal of infectious diseases | | 2008 | 649 | 0 | ||
| Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study | HIV medicine | | 2008 | 646 | 0 | ||
| Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era | AIDS | | 2008 | 702 | 0 | ||
| Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study | Antiviral therapy | | 2008 | 403 | 0 | ||
| Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients | Antiviral therapy | | 2008 | 529 | 0 | ||
| Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006 | HIV medicine | | 2008 | 610 | 0 | ||
| CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy | Clinical infectious diseases | | 2008 | 613 | 0 | ||
| Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy | Pharmacogenetics and genomics | | 2007 | 627 | 0 | ||
| Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study | Antiviral therapy | | 2007 | 621 | 0 | ||
| Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study | AIDS | | 2007 | 591 | 0 | ||
| HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy | Journal of internal medicine | | 2007 | 566 | 0 | ||
| Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study | HIV clinical trials | | 2007 | 582 | 0 | ||
| Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study | Clinical infectious diseases | | 2007 | 522 | 0 | ||
| Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission | Clinical infectious diseases | | 2007 | 577 | 0 | ||
| Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types | Archives of internal medicine | | 2007 | 615 | 0 | ||
| Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study | Antiviral therapy | | 2007 | 519 | 0 | ||
| CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy | Antiviral therapy | | 2007 | 515 | 0 | ||
| Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy | Antiviral therapy | | 2007 | 563 | 0 | ||
| Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification | Antiviral therapy | | 2007 | 583 | 1 | ||
| Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study | HIV medicine | | 2006 | 592 | 0 | ||
| Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study | Antiviral therapy | | 2006 | 489 | 0 | ||
| Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | | 2006 | 477 | 0 | ||
| CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial | Lancet | | 2006 | 669 | 0 | ||
| Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study | Clinical infectious diseases | | 2005 | 680 | 0 | ||
| Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders | The Journal of infectious diseases | | 2005 | 508 | 0 | ||
| HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss | Journal of acquired immune deficiency syndromes | | 2005 | 599 | 0 | ||
| Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study | Antiviral therapy | | 2005 | 518 | 0 | ||
| Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study | Antiviral therapy | | 2005 | 577 | 0 | ||
| Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy | Clinical infectious diseases | | 2005 | 590 | 0 | ||
| The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study | AIDS | | 2004 | 623 | 0 | ||
| Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study | AIDS research and human retroviruses | | 2004 | 649 | 0 | ||
| Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection | Antiviral therapy | | 2004 | 483 | 0 | ||
| Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study | BMJ. British medical journal | | 2004 | 558 | 0 | ||
| Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point | Blood | | 2004 | 626 | 0 | ||
| A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART | AIDS | | 2003 | 543 | 0 | ||
| Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population | Lancet | | 2003 | 582 | 0 | ||
| Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | | 2003 | 567 | 0 | ||
| A prospective trial of structured treatment interruptions in human immunodeficiency virus infection | Archives of internal medicine | | 2003 | 621 | 0 | ||
| Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial | AIDS | | 2003 | 618 | 0 | ||
| CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study | Archives of internal medicine | | 2003 | 571 | 0 | ||
| Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival | AIDS | | 2003 | 542 | 0 | ||
| Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) | AIDS | | 2002 | 443 | 0 | ||
| Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort | AIDS | | 2002 | 584 | 0 | ||
| Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy | AIDS | | 2002 | 567 | 0 | ||
| A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection | The Journal of infectious diseases | | 2002 | 647 | 0 | ||
| Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study | HIV medicine | | 2002 | 534 | 0 | ||
| Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | | 2002 | 484 | 0 | ||
| Epidemiology of methicillin-resistant Staphylococcus aureus: results of a nation-wide survey in Switzerland | Schweizerische medizinische Wochenschrift | | 2002 | 642 | 0 | ||
| HIV transmission after suspension of highly active antiretroviral therapy | Journal of acquired immune deficiency syndromes | | 2001 | 547 | 0 | ||
| Antiretroviral prophylaxis for community exposure to the human immunodeficiency virus in Switzerland, 1997-2000 | Schweizerische medizinische Wochenschrift | | 2001 | 513 | 0 | ||
| Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study | Lancet | | 2001 | 868 | 0 | ||
| Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study | AIDS | | 2001 | 613 | 0 | ||
| Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients | HIV medicine | | 2001 | 609 | 0 | ||
| Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study | Clinical infectious diseases | | 2001 | 550 | 0 | ||
| Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study | AIDS | | 2000 | 491 | 0 | ||
| Zweitinfektion mit HIV: Mythos oder Realitat? | Schweizerische medizinische Wochenschrift | 2000 | 561 | 0 | |||
| Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study | The New England journal of medicine | | 1999 | 521 | 0 | ||
| AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study | JAMA | | 1999 | 606 | 0 | ||
| A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study | AIDS | | 1998 | 505 | 0 | ||
| Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study | Antiviral therapy | 1998 | 504 | 0 | |||
| Low doses of zidovudine plus didanosine are less effective than higher doses of didanosine monotherapy: a randomized trial in patients pretreated with zidovudine | Clinical microbiology and infection | | 1997 | 675 | 0 |
